title: GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.
abstract: OBJECTIVE
  To evaluate the safety and tolerability of natalizumab when added to glatiramer acetate (GA) in patients with relapsing multiple sclerosis. The primary outcome assessed whether this combination would increase the rate of development of new active lesions on cranial MRI scans vs GA alone.
  
  
  METHODS
  This phase 2, randomized, double-blind, placebo-controlled study included patients aged 19 to 55 years who were treated with GA for at least 1 year before randomization and experienced at least one relapse during the previous year. Patients received IV natalizumab 300 mg (n = 55) or placebo (n = 55) once every 4 weeks plus GA 20 mg subcutaneously once daily for < or = 20 weeks.
  
  
  RESULTS
  The mean rate of development of new active lesions was 0.03 with combination therapy vs 0.11 with GA alone (p = 0.031). Combination therapy resulted in lower mean numbers of new gadolinium-enhancing lesions (0.6 vs 2.3 for GA alone, p = 0.020) and new/newly enlarging T2-hyperintense lesions (0.5 vs 1.3, p = 0.029). The incidence of infection and infusion reactions was similar in both groups; no hypersensitivity reactions were observed. One serious adverse event occurred with combination therapy (elective hip surgery). With the exception of an increase in anti-natalizumab antibodies with combination therapy, laboratory data were consistent with previous clinical studies of natalizumab alone.
  
  
  CONCLUSIONS
  The combination of natalizumab and glatiramer acetate seemed safe and well tolerated during 6 months of therapy.
authors.affiliation: Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA. andrew_goodman@urmc.rochester.edu
authors.forename: A D
authors.initials: AD
authors.lastname: Goodman
authors.forename: H
authors.initials: H
authors.lastname: Rossman
authors.forename: A
authors.initials: A
authors.lastname: Bar-Or
authors.forename: A
authors.initials: A
authors.lastname: Miller
authors.forename: D H
authors.initials: DH
authors.lastname: Miller
authors.forename: K
authors.initials: K
authors.lastname: Schmierer
authors.forename: F
authors.initials: F
authors.lastname: Lublin
authors.forename: O
authors.initials: O
authors.lastname: Khan
authors.forename: N M
authors.initials: NM
authors.lastname: Bormann
authors.forename: M
authors.initials: M
authors.lastname: Yang
authors.forename: M A
authors.initials: MA
authors.lastname: Panzara
authors.forename: A W
authors.initials: AW
authors.lastname: Sandrock
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000069442:Natalizumab; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects; D011859:Radiography
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D010455:Peptides; D000068717:Glatiramer Acetate